Wells Fargo’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,796
| Closed | -$43K | – | 7465 |
|
|
2026
Q1 | $43K | Sell |
5,796
-40
| -0.7% | -$260 | ﹤0.01% | 5505 |
|
|
2025
Q4 | $36.7K | Sell |
5,836
-10
| -0.2% | -$58 | ﹤0.01% | 5646 |
|
|
2025
Q3 | $22.8K | Buy |
5,846
+100
| +2% | +$410 | ﹤0.01% | 5765 |
|
|
2025
Q2 | $26.3K | Buy |
5,746
+43
| +0.8% | +$184 | ﹤0.01% | 5712 |
|
|
2025
Q1 | $27.8K | Sell |
5,703
-474
| -8% | -$2.88K | ﹤0.01% | 5601 |
|
|
2024
Q4 | $41.5K | Sell |
6,177
-1,639
| -21% | -$12.2K | ﹤0.01% | 5549 |
|
|
2024
Q3 | $60.4K | Sell |
7,816
-135
| -2% | -$814 | ﹤0.01% | 5275 |
|
|
2024
Q2 | $47.7K | Sell |
7,951
-1,019
| -11% | -$7.75K | ﹤0.01% | 5313 |
|
|
2024
Q1 | $80.9K | Sell |
8,970
-612
| -6% | -$5.58K | ﹤0.01% | 5020 |
|
|
2023
Q4 | $90.8K | Sell |
9,582
-2,066
| -18% | -$18.2K | ﹤0.01% | 4967 |
|
|
2023
Q3 | $139K | Buy |
11,648
+1,389
| +14% | +$24.6K | ﹤0.01% | 4585 |
|
|
2023
Q2 | $251K | Buy |
10,259
+245
| +2% | +$6.38K | ﹤0.01% | 4441 |
|
|
2023
Q1 | $313K | Buy |
10,014
+5,805
| +138% | +$336K | ﹤0.01% | 4157 |
|
|
2022
Q4 | $296K | Sell |
4,209
-448
| -10% | -$33.2K | ﹤0.01% | 3956 |
|
|
2022
Q3 | $400K | Sell |
4,657
-4,014
| -46% | -$390K | ﹤0.01% | 3828 |
|
|
2022
Q2 | $717K | Sell |
8,671
-3,186
| -27% | -$281K | ﹤0.01% | 3513 |
|
|
2022
Q1 | $1.97M | Sell |
11,857
-3,055
| -20% | -$438K | ﹤0.01% | 3317 |
|
|
2021
Q4 | $2.49M | Sell |
14,912
-10,359
| -41% | -$1.17M | ﹤0.01% | 3265 |
|
|
2021
Q3 | $2.18M | Buy |
25,271
+1,079
| +4% | +$71.4K | ﹤0.01% | 3593 |
|
|
2021
Q2 | $1.31M | Sell |
24,192
-1,464
| -6% | -$83.1K | ﹤0.01% | 4023 |
|
|
2021
Q1 | $1.53M | Sell |
25,656
-5,765
| -18% | -$337K | ﹤0.01% | 3929 |
|
|
2020
Q4 | $1.64M | Buy |
31,421
+8,573
| +38% | +$477K | ﹤0.01% | 3632 |
|
|
2020
Q3 | $1.1M | Sell |
22,848
-7,842
| -26% | -$375K | ﹤0.01% | 3783 |
|
|
2020
Q2 | $1.59M | Buy |
30,690
+23,519
| +328% | +$1.19M | ﹤0.01% | 3446 |
|
|
2020
Q1 | $312K | Sell |
7,171
-1,599
| -18% | -$65K | ﹤0.01% | 4393 |
|
|
2019
Q4 | $352K | Buy |
8,770
+4,577
| +109% | +$141K | ﹤0.01% | 4624 |
|
|
2019
Q3 | $138K | Buy |
4,193
+1,105
| +36% | +$53.4K | ﹤0.01% | 5166 |
|
|
2019
Q2 | $238K | Buy |
3,088
+2,321
| +303% | +$361K | ﹤0.01% | 4873 |
|
|
2019
Q1 | $136K | Buy |
767
+509
| +197% | +$100K | ﹤0.01% | 5012 |
|
|
2018
Q4 | $61K | Buy |
258
+25
| +11% | +$6.11K | ﹤0.01% | 5458 |
|
|
2018
Q3 | $50K | Buy |
+233
| New | +$40.7K | ﹤0.01% | 5592 |
|
Wells Fargo's KZR Position: Q2 2026 in Review
Wells Fargo sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 5,796 shares — an estimated $43K sold.
Wells Fargo first reported a position in KZR in Q3 2018 and held it in 31 quarters. The position peaked at $2.49M in Q4 2021. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Wells Fargo reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Wells Fargo sold 5,796 Kezar Life Sciences shares in Q2 2026, an estimated $43K.
- Wells Fargo first reported a position in Kezar Life Sciences in Q3 2018 and held it in 31 quarters.
- Wells Fargo's Kezar Life Sciences position peaked at $2.49M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.